PriceTargets.com logo

Marker Therapeutics - MRKR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.25
  • Forecasted Upside: 752.27%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$1.32 As of 03/19/2026 05:00 PM ET
▼ -0.02 (-1.49%)

This chart shows the closing price for MRKR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Marker Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRKR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRKR

Analyst Price Target is $11.25
▲ +752.27% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Marker Therapeutics in the last 3 months. The average price target is $11.25, with a high forecast of $12.50 and a low forecast of $10.00. The average price target represents a 752.27% upside from the last price of $1.32.

This chart shows the closing price for MRKR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Marker Therapeutics. This rating has held steady since December 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/18/2026
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2026

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/12/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/16/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025HC WainwrightInitiated CoverageBuy ➝ Buy$10.00
12/8/2025UBS GroupReiterated RatingBuy ➝ Buy
12/8/2025HC WainwrightInitiated CoverageBuy ➝ Buy$10.00
11/18/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/1/2025WBB SecuritiesReiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.50
3/5/2025Canaccord Genuity GroupInitiated CoverageBuy$8.00
10/21/2024LADENBURG THALM/SH SHBoost TargetBuy ➝ Buy$11.00 ➝ $19.00
4/30/2024LADENBURG THALM/SH SHInitiated CoverageBuy$11.00
5/27/2022Piper SandlerLower Target$3.50 ➝ $1.50
2/17/2022Roth MkmDowngradeBuy ➝ Neutral$1.00
2/17/2022Piper SandlerLower Target$5.50 ➝ $4.00
3/25/2021Piper SandlerInitiated CoverageOverweight$6.00
(Data available from 3/20/2021 forward)

News Sentiment Rating

0.50 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/20/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Marker Therapeutics logo
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Read More

Today's Range

Now: $1.32
Low: $1.25
High: $1.36

50 Day Range

MA: $1.60
Low: $1.32
High: $2.19

52 Week Range

Now: $1.32
Low: $0.81
High: $4.07

Volume

117,872 shs

Average Volume

126,443 shs

Market Capitalization

$22.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Marker Therapeutics?

The following Wall Street research analysts have issued stock ratings on Marker Therapeutics in the last twelve months: HC Wainwright, UBS Group AG, Wall Street Zen, WBB Securities, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for MRKR.

What is the current price target for Marker Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Marker Therapeutics in the last year. Their average twelve-month price target is $11.25, suggesting a possible upside of 758.8%. WBB Securities has the highest price target set, predicting MRKR will reach $12.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Marker Therapeutics in the next year.
View the latest price targets for MRKR.

What is the current consensus analyst rating for Marker Therapeutics?

Marker Therapeutics currently has 1 sell rating, 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MRKR.

What other companies compete with Marker Therapeutics?

Other companies that are similar to Marker Therapeutics include Tenax Therapeutics, Q32 Bio, BGM Group, Biomea Fusion and Cingulate. Learn More about companies similar to Marker Therapeutics.

How do I contact Marker Therapeutics' investor relations team?

Marker Therapeutics' physical mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company's listed phone number is (713) 400-6400 and its investor relations email address is [email protected]. The official website for Marker Therapeutics is www.markertherapeutics.com. Learn More about contacing Marker Therapeutics investor relations.